[Comment] Radiotherapy-free approach in inoperable locally advanced non-small-cell lung cancer: are we ready for this shift?

Concurrent chemoradiotherapy followed by consolidation with durvalumab is the standard of care for patients with locally advanced non-small-cell lung cancer (NSCLC) who are medically or surgically inoperable, have a good performance status, and do not have actionable EGFR mutations.1 In the PACIFIC trial, consolidation treatment with durvalumab for up to 12 months after platinum-based chemoradiotherapy showed a 5-year progression-free survival rate of 33·1% (95% CI 28·0–38·2) and 5-year overall survival rate of 42·9% (38·2–47·4).